Tryptophyl-tyrosin-dipeptid | 22032-67-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Tryptophyl-tyrosin-dipeptid
• 英文别名: 2-[[2-azaniumyl-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoate
• CAS: 22032-67-3；60815-41-0
• 化学式: C₂₀H₂₁N₃O₄
• 分子量: 367.404
• InChiKey: BMPPMAOOKQJYIP-UHFFFAOYSA-N

物化性质

• 沸点：
  747.9±60.0 °C(Predicted)
• 密度：
  1.387±0.06 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  128
• 氢给体数：
  5
• 氢受体数：
  5

制备方法与用途

酪氨酸和色氨酸是一种具有生物活性的肽。

反应信息

• 作为反应物：
  描述：

  [(η6-cymene)Ru(acetone)3](CF3SO3)2 、 Tryptophyl-tyrosin-dipeptid 、 三氟乙酸 以 三氟乙酸 为溶剂， 以73%的产率得到[(η6-cymene)Ru(eta.6-C8H6NCH2CH(COOH)NHC(O)CH(NH2)CH2C6H4OH)](CF3SO3)2*CF3COOH
  参考文献：
  名称：

  Functional mono- and dinuclear peptide complexes featuring chemospecific κS- or η6-coordination of organometallic half-sandwich fragments

  摘要：

  Treatment of the dipeptides H-Tyr-Trp-OH, H-Trp-Tyr-OH, H-Trp-Phe-OH and H-Phe-Tyr-OH with [(T,(6)- cymene)Ru(acetone)(3)].(CF3SO3)(2) (1) in CF3COOH leads to chemospecific eta(6)-coordination in the order of electron-donating ability Trp > Tyr > Phe in respective complexes of the type [(eta(6)-cymene)Ru(eta(6) -dipeptide)](CF3SO3)(2) (3-6) after 24-36 h at 20degreesC. An analogous thermodynamic chemospecificity was also established for the complexes [(eta(5) -Cp*)Ir(eta(6)-dipeptide)](CF3SO3)(2) (7, H-Phe-Trp-OH; 8, H-Phe-Tyr-OH). However, a time-dependent 1H NMR study of the reaction between [(eta(5) -Cp*)Ir(acetone)(3)] (CF3SO3)(2) (2) and H-Tyr-Phe-OH confirms an initial kinetic preference for eta(6)-coordination of the C-terminal arene, as is also apparent from product mixtures obtained after treating 2 with H-Trp-Phe-OH or H-Trp-Tyr-OH for 1-2 d at 50 degreesC. Dinuclear sandwich complexes of the type [(eta(5)-Cp *)Ir(mu(2)-H-Met-X-OH-eta(6)-X:kappa(2)N(M), S)Pt(en)](CF3SO3)(4) (9-11, X = Phe, Tyr, Trp) can be prepared in CF3COOH following initial N-terminal kappa(2)N(M), S chelation of the (en)Pt-II fragment by the methionine residue of the dipeptide. Chemospecific kappaS coordination of the [(eta(5)-Cp *)Ir(dppZ)](2+) fragment in [(eta(5)-Cp*)Ir(dppz) (H-2-HArg-Met-NH2-kappaS)](4+) (12), [{(eta(5)-Cp*)Ir(dppz)}(2)(mu-H-2-Met -Met-OH-kappaS:kappaS')](5+) (13) and [(eta(5)-Cp*)Ir(dppz)(mu-H-Gly-Met-OH-kappaS:kappaN(G))Pt(terpy)](4+) (14) affords effective metallointercalators for DNA with binding constants K-b in the range 1.3-3.3 x 10(6) M-1 and marked melting temperature shifts DeltaT(m) of respectively 10.2, 15.2 and 11.2 degreesC. (C) 2003 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/s0020-1693(03)00345-1

文献信息

• Nutrient compositions containing peptides
  申请人：CLINTEC NUTRITION COMPANY

  公开号：EP0457314A1

  公开（公告）日：1991-11-21

  Nutrient compositions comprise an aqueous solution of at least one dipeptide with an N-terminal amino acid selected from glutamine, aspargine, tyrosine, tryptophan, and aspargine. The C-terminal amino acid is alanine, glycine, tryptophan, arginine, proline or serine. The nutritional compositions contain from about 0.1 to 25.0 percent by weight of oligopeptides, preferably about 0.5 to 5.0 percent by weight.

  营养组合物包含至少一种二肽的水溶液，其 N 端氨基酸选自谷氨酰胺、天门冬氨酸、酪氨酸、色氨酸和天门冬氨酸。 C 端氨基酸为丙氨酸、甘氨酸、色氨酸、精氨酸、脯氨酸或丝氨酸。营养组合物含有约 0.1%至 25.0%（按重量计）的低聚肽，最好是约 0.5%至 5.0%（按重量计）。
• ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM
  申请人：Ajinomoto Co., Inc.

  公开号：EP3604503A1

  公开（公告）日：2020-02-05

  The present invention provides a medium for culturing pluripotency stem cells, containing L-tryptophan or L-tryptophan derivative at a concentration of not less than 176 µM.

  本发明提供了一种培养多能干细胞的培养基，其中含有浓度不低于 176 µM 的 L-色氨酸或 L-色氨酸衍生物。
• PRECISE ESTIMATION OF GLOMERULAR FILTRATION RATE FROM MULTIPLE BIOMARKERS
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20170276669A1

  公开（公告）日：2017-09-28

  The present invention relates to the field of nephrology. More specifically, the present invention provides methods and compositions useful for more precisely estimating glomerular filtration rate (GFR). In a specific embodiment, a method for calculating the estimated glomerular filtration rate (eGFR) in a patient comprises the steps of (a) measuring the level of one or more metabolites using mass spectrometry from a blood sample obtained from the patient; and (b) calculating the eGFR using an algorithm that utilizes the measured levels of the one or more metabolites.
• [EN] PROTEIN GLYCATION SUPPRESSANT<br/>[FR] SUPPRESSEUR DE GLYCATION DE PROTÉINE<br/>[JA] タンパク質糖化抑制剤
  申请人：AJINOMOTO KK

  公开号：WO2020071258A1

  公开（公告）日：2020-04-09

  本発明の課題は、優れた抗糖化機能を示す組成物等を提供する。特に、幅広い終末糖化産物に対して抗糖化機能を示し、さらに抗酸化機能を有しつつ、化粧料等に使用しても着色し難く、安全性・生体適合性の高い成分を提供すること、幅広い終末糖化産物に対して抗糖化機能を示し、さらに抗酸化機能を有しつつ、安定性、安全性、生体適合性の高い成分を含む組成物等を提供すること。本発明は、炭素原子数が３以上の中性アミノ酸又はその塩を有効成分として含有することを特徴とするタンパク質糖化抑制剤、並びに酸性アミノ酸、塩基性アミノ酸、ヒドロキシアミノ酸、分岐鎖アミノ酸、及び抗酸化性のアミノ酸からなる群から選ばれるアミノ酸を構成アミノ酸とし、且つＣ末端側の構成アミノ酸が、抗酸化性のアミノ酸であるジペプチド又はその塩を有効成分として含有することを特徴とするタンパク質糖化抑制剤。